​

Quince Therapeutics (QNCX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

QNCX Stock Forecast

Quince Therapeutics (QNCX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $70.00, with a high of $70.00 and a low of $70.00. This represents a 112.70% increase from the last price of $32.91.

- $14 $28 $42 $56 $70 High: $70 Avg: $70 Low: $70 Last Closed Price: $32.91

QNCX Stock Rating

Quince Therapeutics stock's rating consensus is Hold, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (36.36%), 5 Hold (45.45%), 2 Sell (18.18%), and 0 Strong Sell (0.00%).

Hold
Total 11 0 2 5 4 Strong Sell Sell Hold Buy Strong Buy

QNCX Price Target Upside V Benchmarks

TypeNameUpside
StockQuince Therapeutics112.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$70.00$70.00$70.00
Last Closing Price$32.91$32.91$32.91
Upside/Downside112.70%112.70%112.70%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Aug, 26-42--6
Jul, 26-33--6
Jun, 26-23--5
May, 26--3--3
Apr, 26--3--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 18, 2026Olivia Brayer SaundersCantor Fitzgerald$70.00$32.91112.70%112.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 18, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 29, 2026OppenheimerOutperformOutperforminitialise
Jun 25, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 23, 2026Cantor FitzgeraldOverweightinitialise
Jan 30, 2026CitigroupMarket PerformPerformdowngrade
Jan 30, 2026CitigroupMarket OutperformMarket Performdowngrade
Jan 06, 2026CitigroupMarket OutperformMarket Outperformhold
Aug 05, 2025CitigroupOutperforminitialise
Mar 24, 2025OppenheimerOutperforminitialise
Oct 29, 2024Rodman & RenshawBuyinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.84$-1.31$-1.68---
Avg Forecast$-1.33$-1.22$-0.66$-0.63$-0.30$0.38
High Forecast$-1.33$-1.22$-0.66$-0.14$0.05$0.38
Low Forecast$-1.33$-1.22$-0.66$-1.06$-0.82$0.38
Surprise %-36.84%7.38%154.55%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast----$48.91M$232.47M
High Forecast----$48.91M$232.47M
Low Forecast----$48.91M$232.47M
Surprise %------

Net Income Forecast

$-85M $-65M $-45M $-25M $-5M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.39M$-56.83M$-83.98M---
Avg Forecast$-49.52M$-45.34M$-24.70M$-22.34M$-15.86M$14.03M
High Forecast$-49.52M$-45.34M$-24.70M$-5.21M$1.86M$14.03M
Low Forecast$-49.52M$-45.34M$-24.70M$-39.47M$-30.53M$14.03M
Surprise %-36.62%25.35%239.99%---

QNCX Forecast FAQ

Is Quince Therapeutics stock a buy?

Quince Therapeutics stock has a consensus rating of Hold, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 5 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Quince Therapeutics is a neutral investment for most analysts.

What is Quince Therapeutics's price target?

Quince Therapeutics's price target, set by 11 Wall Street analysts, averages $70 over the next 12 months. The price target range spans from $70 at the low end to $70 at the high end, suggesting a potential 112.70% change from the previous closing price of $32.91.

How does Quince Therapeutics stock forecast compare to its benchmarks?

Quince Therapeutics's stock forecast shows a 112.70% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Quince Therapeutics over the past three months?

  • August 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.

What is Quince Therapeutics’s EPS forecast?

Quince Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.63, marking a -62.50% decrease from the reported $-1.68 in 2025. Estimates for the following years are $-0.3 in 2027, and $0.38 in 2028.

What is Quince Therapeutics’s revenue forecast?

Quince Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $0, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $48.91M, and $232.47M for 2028.

What is Quince Therapeutics’s net income forecast?

Quince Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-22.342M, representing a -73.40% decrease from the reported $-83.979M in 2025. Projections indicate $-15.864M in 2027, and $14.03M in 2028.